IBDEI0UN ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14103,0)
 ;;=H40.33X4^^82^770^124
 ;;^UTILITY(U,$J,358.3,14103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14103,1,3,0)
 ;;=3^Traumatic Glaucoma,Bilateral,Indeterminate Stage
 ;;^UTILITY(U,$J,358.3,14103,1,4,0)
 ;;=4^H40.33X4
 ;;^UTILITY(U,$J,358.3,14103,2)
 ;;=^5005864
 ;;^UTILITY(U,$J,358.3,14104,0)
 ;;=H21.233^^82^770^26
 ;;^UTILITY(U,$J,358.3,14104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14104,1,3,0)
 ;;=3^Degeneration of Iris,Bilateral
 ;;^UTILITY(U,$J,358.3,14104,1,4,0)
 ;;=4^H21.233
 ;;^UTILITY(U,$J,358.3,14104,2)
 ;;=^5005189
 ;;^UTILITY(U,$J,358.3,14105,0)
 ;;=H40.61X1^^82^770^40
 ;;^UTILITY(U,$J,358.3,14105,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14105,1,3,0)
 ;;=3^Drug-Induced Glaucoma,Right Eye,Mild Stage
 ;;^UTILITY(U,$J,358.3,14105,1,4,0)
 ;;=4^H40.61X1
 ;;^UTILITY(U,$J,358.3,14105,2)
 ;;=^5005907
 ;;^UTILITY(U,$J,358.3,14106,0)
 ;;=H40.013^^82^770^59
 ;;^UTILITY(U,$J,358.3,14106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14106,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,14106,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,14106,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,14107,0)
 ;;=H40.012^^82^770^60
 ;;^UTILITY(U,$J,358.3,14107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14107,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,14107,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,14107,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,14108,0)
 ;;=H40.011^^82^770^61
 ;;^UTILITY(U,$J,358.3,14108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14108,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,14108,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,14108,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,14109,0)
 ;;=H40.023^^82^770^84
 ;;^UTILITY(U,$J,358.3,14109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14109,1,3,0)
 ;;=3^Open-Angle w/ Borderline Findings,Hi Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,14109,1,4,0)
 ;;=4^H40.023
 ;;^UTILITY(U,$J,358.3,14109,2)
 ;;=^5005730
 ;;^UTILITY(U,$J,358.3,14110,0)
 ;;=H40.063^^82^770^108
 ;;^UTILITY(U,$J,358.3,14110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14110,1,3,0)
 ;;=3^Primary Angle-Closure w/o Glaucoma Damage,Bilateral
 ;;^UTILITY(U,$J,358.3,14110,1,4,0)
 ;;=4^H40.063
 ;;^UTILITY(U,$J,358.3,14110,2)
 ;;=^5005746
 ;;^UTILITY(U,$J,358.3,14111,0)
 ;;=H40.243^^82^770^113
 ;;^UTILITY(U,$J,358.3,14111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14111,1,3,0)
 ;;=3^Residual Stage Angle-Closure Glaucoma,Bilateral
 ;;^UTILITY(U,$J,358.3,14111,1,4,0)
 ;;=4^H40.243
 ;;^UTILITY(U,$J,358.3,14111,2)
 ;;=^5005845
 ;;^UTILITY(U,$J,358.3,14112,0)
 ;;=H40.043^^82^770^121
 ;;^UTILITY(U,$J,358.3,14112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14112,1,3,0)
 ;;=3^Steroid Responder,Bilateral
 ;;^UTILITY(U,$J,358.3,14112,1,4,0)
 ;;=4^H40.043
 ;;^UTILITY(U,$J,358.3,14112,2)
 ;;=^5005738
 ;;^UTILITY(U,$J,358.3,14113,0)
 ;;=B02.39^^82^771^10
 ;;^UTILITY(U,$J,358.3,14113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14113,1,3,0)
 ;;=3^Herpes Zoster Eye Disease NEC
 ;;^UTILITY(U,$J,358.3,14113,1,4,0)
 ;;=4^B02.39
 ;;^UTILITY(U,$J,358.3,14113,2)
 ;;=^5000498
 ;;^UTILITY(U,$J,358.3,14114,0)
 ;;=B00.59^^82^771^9
 ;;^UTILITY(U,$J,358.3,14114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14114,1,3,0)
 ;;=3^Herpes Viral Eye Disease NEC
 ;;^UTILITY(U,$J,358.3,14114,1,4,0)
 ;;=4^B00.59
 ;;^UTILITY(U,$J,358.3,14114,2)
 ;;=^5000476
 ;;^UTILITY(U,$J,358.3,14115,0)
 ;;=B25.9^^82^771^8
 ;;^UTILITY(U,$J,358.3,14115,1,0)
 ;;=^358.31IA^4^2
